The week in health tech, explained in plain English.Get the free newsletter →
November 18, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

Versant and Lilly Back $100M Gene Therapy Startup

Versant Ventures, Eli Lilly, and a group of additional investors are committing $100 million to launch a new startup aimed at tackling one of gene therapy's most persistent problems, according to STAT News.

The backing matters because gene therapy has delivered dramatic clinical results but remains held back by stubborn technical and commercial obstacles, including how to deliver genetic payloads safely, how to make effects durable, and how to manufacture treatments at scale and reasonable cost. A $100 million round led by a top-tier venture firm and a major pharmaceutical company signals that investors still see large upside in solving these foundational issues rather than chasing individual disease programs.

For operators and investors, the deal is a reminder that capital is flowing toward platform-level fixes in gene therapy, where a breakthrough could unlock many downstream treatments. Eli Lilly's involvement also reflects how large drugmakers are partnering early with startups to secure access to next-generation delivery and durability technology.

Sources

More in Finance

Finance

Optum to Sell New York Physician Practices to 2 Health Systems

Optum is selling New York physician practice assets to Northwell Health and Westchester Medical Center, with Lenox Hill Hospital taking over former CareMount and ProHealth operations.

Why it matters: The sale signals UnitedHealth's Optum is willing to shed physician assets even as it dominates US care delivery, reshaping ownership for New York patients and doctors.

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.